Parallax Volatility Advisers
MDGL icon

Parallax Volatility Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Parallax Volatility Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,600
Closed -$234K – 2370
2023
Q3 		$234K Buy
+1,600
New +$301K ﹤0.01% 1781
2023
Q2 		– Sell
-7,400
Closed -$1.79M – 2712
2023
Q1 		$1.79M Sell
7,400
-15,600
-68% -$4.25M ﹤0.01% 1267
2022
Q4 		$6.68M Buy
+23,000
New +$2.25M 0.01% 925

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parallax Volatility Advisers's MDGL Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 9 shares — an estimated $1.57K sold.

Parallax Volatility Advisers first reported a position in MDGL in Q4 2017 and held it in 5 quarters. The position peaked at $747K in Q1 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

  • Parallax Volatility Advisers reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 9 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $1.57K.
  • Parallax Volatility Advisers first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Madrigal Pharmaceuticals position peaked at $747K in Q1 2023.
  • 226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.